Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Freedom Finance and Binance Join Forces in Digital Assets 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
EXTON, Pa., May 03, 2018 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2018 and recent operational highlights on Thursday, May 10, 2018 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 866-548-4713 (domestic) or +1-323-794-2093 (international), and provide the conference code 3897293 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo, and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact:
Karen Casey
484-713-6133
[email protected]
